SCHEMBL1838586

SCHEMBL1838586

Nc1nccc(-c2c[nH]c3nccc(CCCO)c23)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 15/20 0.60
CDK5R1 Q15078 15/20 0.60
CCNT1 O60563 12/20 0.60
CDK9 P50750 12/20 0.60
CDK2 P24941 12/20 0.60
CCNA2 P20248 11/20 0.60
CCNA1 P78396 9/20 0.60
PDPK1 O15530 2/20 0.51
GSK3B P49841 6/20 0.48
CCNB2 O95067 4/20 0.48
CDK1 P06493 4/20 0.48
CCNB1 P14635 4/20 0.48
PRKACA P17612 4/20 0.48
PRKACG P22612 4/20 0.48
PRKACB P22694 4/20 0.48
CCNB3 Q8WWL7 4/20 0.48
HTR1A P08908 2/20 0.48
HTR2B P41595 2/20 0.48
SLC6A3 Q01959 1/20 0.48
CSNK1A1 P48729 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13521485 0.96 CDK5 (0.58) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL2984404 0.88 CDK5 (0.64) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL13521496 0.87 CDK5 (0.65) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL2999928 0.87 CDK5 (0.63) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL2989519 0.86 CDK5 (0.61) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL2988085 0.85 CDK5 (0.67) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL2991132 0.85 CDK5 (0.58) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL1841178 0.85 CDK5 (0.57) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL12355043 0.83 CDK5 (0.67) CDK5CDK5R1CCNT1CDK9CDK2
SCHEMBL2238419 0.82 CDK5 (0.69) CDK5CDK5R1CCNT1CDK9CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 CDK5 24/4885CDK5R1 41/4885CCNT1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.